PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 1 year 4 months ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
BRIEF published on 03/27/2025 at 07:35, 1 year 4 months ago MaaT Pharma announces a capital increase of 13 million euros and 2024 annual results Financial Results Biotechnology Capital Increase MaaT013 AGvH
BRIEF published on 01/21/2025 at 18:05, 1 year 6 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 8 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 1 year 10 months ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
BRIEF published on 09/04/2024 at 07:35, 1 year 11 months ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
BRIEF published on 05/15/2024 at 07:35, 2 years 3 months ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
PRESS RELEASE published on 05/15/2024 at 07:30, 2 years 3 months ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
Published on 08/15/2026 at 00:15, 2 days 5 hours ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 2 days 5 hours ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:00, 2 days 6 hours ago Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
Published on 08/17/2026 at 02:00, 3 hours 30 minutes ago Sandoz announces strategic collaboration with Henlius on up to 10 biosimilars, further expanding industry-leading pipeline
Published on 08/16/2026 at 19:40, 9 hours 50 minutes ago APIC delivers 55% EBITDA growth in the first half of 2026, reaching USD 44 million
Published on 08/16/2026 at 13:40, 15 hours 50 minutes ago Ajax says goodbye to Godts with a classy message in Paris: THE FUTURE BELONGS TO YOUNG GODTS
Published on 08/16/2026 at 09:45, 19 hours 45 minutes ago Ragnarok Zero: Global Set to Officially Launch on August 18
Published on 08/16/2026 at 06:15, 23 hours 15 minutes ago Garvee Spotlights Home & Garden Essentials for the Late-Summer to Early-Autumn Transition
Published on 08/10/2026 at 18:00, 6 days 11 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 6 days 17 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 6 days 17 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 6 days 20 hours ago Number of shares and voting rights - July 2026 (In French only)
